Health Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note July 5, 2022
Biotech Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN) July 5, 2022
Health Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) July 5, 2022
Biotech Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 5, 2022
Biotech Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022 July 5, 2022
Biotech BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) July 1, 2022
Biotech BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) July 1, 2022